Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.
Market Cap | 175.139 Million | Shares Outstanding | 76.48 Million | Avg 30-day Volume | 4.048 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.58 |
Price to Revenue | 0.0 | Debt to Equity | 7.4355 | EBITDA | -205.011 Million |
Price to Book Value | 21.8431 | Operating Margin | 0.0 | Enterprise Value | 611.325 Million |
Current Ratio | 8.122 | EPS Growth | 0.101 | Quick Ratio | 7.858 |
1 Yr BETA | 1.1323 | 52-week High/Low | 15.2 / 1.57 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -0.282 | Altman Z-Score | -4.0088 | Free Cash Flow to Firm | -142.59 Million |
Earnings Report | 2023-03-02 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HASNAIN FAHEEM PRESIDENT & CEO |
|
544,500 | 2022-12-07 | 3 |
CHRISTIAN WAAGE EVP, TECH OPS AND ADMIN |
|
157,500 | 2022-12-07 | 3 |
GIRAUDO BRYAN COO/CFO |
|
211,500 | 2022-12-07 | 3 |
PETERSON CARYN EVP, REGULATORY AFFAIRS |
|
157,500 | 2022-12-07 | 3 |
CARTER LAURA CHIEF SCIENTIFIC OFFICER |
|
157,500 | 2022-12-07 | 7 |
ARANDA RICHARD CHIEF MEDICAL OFFICER |
|
157,500 | 2022-12-07 | 4 |
|
30,000 | 2022-06-09 | 1 | |
|
30,000 | 2022-06-09 | 1 | |
|
30,000 | 2022-06-09 | 1 | |
|
30,000 | 2022-06-09 | 1 | |
|
30,000 | 2022-06-09 | 1 | |
|
30,000 | 2022-06-09 | 1 | |
SALTER-CID LUISA CHIEF SCIENTIFIC OFFICER |
|
206,065 | 2021-03-23 | 0 |
DUPONT JAKOB CHIEF MEDICAL OFFICER |
|
46,500 | 2020-02-14 | 0 |
GUJRATHI SHEILA PRESIDENT & CEO |
|
4,237,742 | 2020-02-14 | 0 |
|
No longer subject to file | 2019-09-20 | 0 | |
|
6,737,023 | 2019-09-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-12-09 17:13:40 -0500 | 2022-12-07 | A | 544,500 | a | 544,500 | direct | ||||||||||
2022-12-09 17:15:26 -0500 | 2022-12-07 | A | 211,500 | a | 211,500 | direct | ||||||||||
2022-12-09 17:17:41 -0500 | 2022-12-07 | A | 157,500 | a | 157,500 | direct | ||||||||||
2022-12-09 17:18:58 -0500 | 2022-12-07 | A | 157,500 | a | 157,500 | direct | ||||||||||
2022-12-09 17:20:28 -0500 | 2022-12-07 | A | 157,500 | a | 157,500 | direct | ||||||||||
2022-12-09 17:21:46 -0500 | 2022-12-07 | A | 157,500 | a | 157,500 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
GOSSAMER BIO INC GOSS | 2023-01-26 22:15:03 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 21:45:03 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 21:15:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 20:45:03 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 20:15:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 19:45:03 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 19:15:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 18:45:03 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 18:15:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 17:45:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 17:15:04 UTC | 3.241 | 1.079 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 16:45:03 UTC | 3.2409 | 1.0791 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 16:15:04 UTC | 3.2409 | 1.0791 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 15:45:03 UTC | 3.2409 | 1.0791 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 15:15:04 UTC | 3.2409 | 1.0791 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 14:45:04 UTC | 3.242 | 1.078 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 14:15:03 UTC | 3.242 | 1.078 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 13:45:03 UTC | 3.242 | 1.078 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 13:15:04 UTC | 3.242 | 1.078 | 85000 |
GOSSAMER BIO INC GOSS | 2023-01-26 12:45:04 UTC | 3.242 | 1.078 | 85000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | GOSS | -298.0 shares, $-3024.7 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | GOSS | -278.0 shares, $-2821.7 | 2020-03-31 | N-PORT |
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund | GOSS | -54310.0 shares, $-757624.5 | 2022-08-31 | N-PORT |
JNL Series Trust- JNL Multi-Manager Alternative Fund | GOSS | -81465.0 shares, $-975950.7 | 2022-09-30 | N-PORT |
FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND | GOSS | -160100.0 shares, $-1917998.0 | 2022-09-30 | N-PORT |
LAZARD FUNDS INC- Lazard Enhanced Opportunities Portfolio | GOSS | -24015.0 shares, $-287699.7 | 2022-09-30 | N-PORT |